Key Events – And Potential Catalysts – For Biotech Stocks This Week
After a week that saw mostly strong earnings reports from big pharma companies, an Alzheimer’s conference that moved stocks, and a slew of IPOs of…
These 19 “Moaty” Small-Caps Are High-Quality & Undervalued
Smaller-cap companies have had a good 12 months, and the author of today’s article notes that “the return picture over the trailing three-year period suggests…
Will August Bring FDA Approvals For These Biotech Stocks?
With just a few days remaining in July, the FDA has approved four novel drugs this month, including a treatment for a parasitic “sleeping sickness”…
Already Experiencing Great Runs, These 3 Drug Makers Could Explode Higher
“All of these companies are working on new drugs that could be worth billions, and successes with them would push their stock prices through the…
Focus In The Biotech Sector Could Soon Turn To These Therapeutic Areas And Companies
While vaccine makers have gotten most of the attention in the biotech sector over the past year, the author of today’s article advises that other…
Why Synthetic Biology Could Be An Internet-Level Investment Opportunity – And How To Play It
“This is what it might have been like 25 years ago if some guy had walked up to you and said the internet was going…
Biotech Buys: 2 Top Picks Under $10
As a result of the pandemic, investors have likely become familiar with a number of biotech names over the past year and a half that…
A Speculative Stock For What May Be “The Next Big Thing To Sweep Through Biotech”
The company discussed in today’s article is a potential leader in a burgeoning field that the author declares “has the potential to revolutionize medicine in…
A Lower-Risk Way To Play This “High-Octane” Healthcare Trend
A lower-risk way to play a “high-octane” healthcare trend is what the nine exchange-traded funds highlighted in today’s article offer. That trend? Biotechnology. And while…
While Biotech Underperformed In The First Half Of 2021, These Names Stood Out With Solid Gains
While biotech stocks underperformed the broader market in the first half of the year, some names – particularly those focused on neurodegenerative diseases and cancer…